Palisade Bio Shares Are Trading Higher After the Company Announced the Presentation of Data From Two Studios Showing Ex Vivo Bioactivation of PALI-2108 in the Treatment of Ulcerative Colitis.
Palisade Bio Shares Are Trading Higher After the Company Announced the Presentation of Data From Two Studios Showing Ex Vivo Bioactivation of PALI-2108 in the Treatment of Ulcerative Colitis.
帕利薩特生物股票正在上漲,因爲公司宣佈了來自兩個研究所的數據展示PALI-2108在潰瘍性結腸炎治療中的體外生物活化。
Palisade Bio Shares Are Trading Higher After the Company Announced the Presentation of Data From Two Studios Showing Ex Vivo Bioactivation of PALI-2108 in the Treatment of Ulcerative Colitis.
帕利塞德生物股票交易較高,公司宣佈來自兩個研究所的數據展示PALI-2108在治療潰瘍性結腸炎中的離體生物活化。